<div id="readability-page-1"><p>NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.07), Zacks reports. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $6.83 million.</p><div><p><span></span><span>Get <strong>NRx Pharmaceuticals</strong> alerts:</span></p></div><h2>NRx Pharmaceuticals Stock Down 3.9%</h2><p>Shares of NASDAQ:NRXP traded down $0.10 during trading on Friday, hitting $2.49. The stock had a trading volume of 432,261 shares, compared to its average volume of 475,505. NRx Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $6.01. The stock has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $2.87. The stock has a market capitalization of $49.33 million, a price-to-earnings ratio of -1.11 and a beta of 1.76. </p><h2>Institutional Investors Weigh In On NRx Pharmaceuticals</h2><p>Hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP raised its position in  NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after acquiring an additional 20,880 shares during the period.  Geode Capital Management LLC raised its position in shares of  NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter.  Finally, Vanguard Group Inc. lifted its stake in  NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Hedge funds and other institutional investors own  4.27% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts recently commented on NRXP shares. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright  restated a &#34;buy&#34; rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 30th. Finally, D. Boral Capital  restated a &#34;buy&#34; rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.75.</p><p><b>View Our Latest Analysis on NRXP</b></p><h2>About NRx Pharmaceuticals</h2> (Get Free Report)<p>NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than NRx Pharmaceuticals</li><li>Trading Halts Explained</li><li>3 Under-the-Radar AI Stocks to Buy on the Dip</li><li>What is the Nikkei 225 index?    </li><li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li><li>3 REITs to Buy and Hold for the Long Term</li><li>MarketBeat Week in Review – 11/10 - 11/14</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA"/></p><h2>Should You Invest $1,000 in NRx Pharmaceuticals Right Now?</h2><p>Before you consider NRx Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.</p><p>While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NRXP

<p>NRx Pharmaceuticals (NASDAQ:NRXP) reported a quarterly loss of $0.18 per share, missing the consensus estimate of $0.08. The company had revenue of $0.24 million, below the expected $6.83 million. Shares fell 3.9% to $2.49. Institutional investors increased their holdings, and analysts have mixed ratings with a consensus price target of $34.75. NRx develops treatments for central nervous system disorders.</p>

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results